Abstract:SARS-CoV-2 is the novel coronavirus causing the COVID-19 pandemic. To enter human cells, the receptor-binding domain (RBD) of the S1 subunit of SARS-CoV-2 (SARS-CoV-2-RBD) initially binds to the peptidase domain of angiotensin-converting enzyme 2 receptor (ACE2-PD). Using peptides to inhibit SARS-CoV-2-RBD binding to ACE2 is a potential therapeutic solution for COVID-19. A previous study identified a 23-mer peptide (SBP1) that bound to SARS-CoV-2-RBD with comparable KD to ACE2. We employed computational protein design and molecular dynamics (MD) to design SARS-CoV-2-RBD 25-mer peptide binders (SPB25) with better predicted binding affinity than SBP1. Using residues 21–45 of the α1 helix of ACE2-PD as the template, our strategy is employing Rosetta to enhance SPB25 binding affinity to SARS-CoV-2-RBD and avoid disrupting existing favorable interactions by using residues that have not been reported to form favorable interactions with SARS-CoV-2-RBD as designed positions. Designed peptides with better predicted binding affinities, by Rosetta, than SPB25 were subjected to MD validation. The MD results show that five designed peptides (SPB25F8N, SPB25F8R, SPB25L25R, SPB25F8N/L25R, and SPB25F8R/L25R) have better predicted binding affinities, by the MM-GBSA method, than SPB25 and SBP1. This study developed an approach to design SARS-CoV-2-RBD peptide binders, and these peptides may be promising candidates as potential SARS-CoV-2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jpcb.0c07890?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jpcb.0c07890</a>.rmsd plots of ACE2, SBP1, SPB25, and designed peptides in complex with SARS-CoV-2-RBD; rmsd plots of ACE2, SBP1, SPB25, and designed peptides in water; binding free energies of ACE2, SBP1, SPB25, and all designed peptides to SARS-CoV-2-RBD, as calculated with Rosetta and the MM-GBSA method; and hydrogen bond occupations of ACE2, SBP1, SPB25, and designed peptide binding to SARS-CoV-2-RBD (<a class="ext-link" href="/doi/suppl/10.1021/acs.jpcb.0c07890/suppl_file/jp0c07890_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Site-Specific Covalent Immobilization of SMA-Stabilized ACE2 for SARS-CoV-2 Recognition and Drug Screening.

A surface molecularly imprinted electrochemical biosensor for the detection of SARS-CoV-2 spike protein by using Cu 7 S 4 -Au as built-in probe

Deciphering ACE2-RBD binding affinity through peptide scanning: A molecular dynamics simulation approach

Dual coiled-coil protein domain mimic and drug delivery vehicle for SARS-CoV-2

An anti-fouling surface molecularly imprinted ratiometric electrochemical biosensor for SARS-CoV-2 spike protein

Robust Covalent Aptamer Strategy Enables Sensitive Detection and Enhanced Inhibition of SARS-CoV-2 Proteins

Rational design based on multi-monomer simultaneous docking for epitope imprinting of SARS-CoV-2 spike protein

Chemical Proteomics Approaches for Screening Small Molecule Inhibitors Covalently Binding to SARS-Cov-2

Peptidic Sulfhydryl for Interfacing Nanocrystals and Subsequent Sensing of SARS-CoV-2 Protease

Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors

In Situ Surface-Enhanced Raman Scattering Detection of a SARS-CoV-2 Biomarker Using Flexible and Transparent Polydimethylsiloxane Films with Embedded Au Nanoplates

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry

Engineering a "muco‐trapping" ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants

Computational Design of 25-mer Peptide Binders of SARS-CoV-2

Covalent Bonding Aptamer with Enhanced SARS-CoV-2 RBD-ACE2 Blocking and Pseudovirus Neutralization Activities

An antifouling electrochemical sensor integrating ''3-in-1′′ dual-targeted aptamer for the detection of the SARS-CoV-2 spike protein

Dendrimer-Peptide Conjugates for Effective Blockade of the Interactions Between SARS-CoV-2 Spike Protein and Human ACE2 Receptor

Bioscreening specific peptide-expressing phage and its application in sensitive dual-mode immunoassay of SARS-CoV-2 spike antigen

Angiotensin-Converting Enzyme 2 (ACE2) As a Novel Biorecognition Element in A Cell-Based Biosensor for the Ultra-Rapid, Ultra-Sensitive Detection of the SARS-CoV-2 S1 Spike Protein Antigen